Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Amy Toro advises both pharmaceutical and biotechnology companies regarding biologics, pharmaceuticals and devices, including in the digital health space. Ms. Toro works on all types of life sciences transactions, including major collaborations, licensing arrangements, clinical trial agreements, supply and distribution agreements, product development funding deals, and joint ventures and a variety of commercial agreements. She also works with her mergers and acquisition colleagues on product divestitures and asset transfers.

  • Representing a start-up company in possible spin-out license from a large pharmaceutical company.
  • Representing Amyris, Inc., a biotechnology company focused on biofuels, in joint venture and other commercial transactions with Total and other strategic collaboration partners.
  • Represented Gilead Sciences, Inc., in negotiating multiple agreements with Tibotec Pharmaceuticals for the development and commercialization of three different combination products for the treatment of HIV.
  • Represented Sanofi U.S. in multiple license and collaboration agreements, including an out-license agreement of a nasal inhalant product for the treatment of allergies.
  • Represented AstraZeneca in negotiating an in-license agreement with Nektar Therapeutics to develop and commercialize a pegylated opioid product, including for the treatment of opioid-induced constipation.
  • Represented Lilly in negotiating certain manufacturing arrangements relating to its agreement with Evonik for the sale of its Tippecanoe facility.
  • Represented Boehringer-Ingelheim in negotiating certain manufacturing arrangements relating to its purchase of animal health assets from Pfizer, Inc..
  • Advised Novartis regarding a vaccine technology transfer agreement with a government-owned Brazilian pharmaceutical company. 
  • Represented Gilead Sciences, Inc., in negotiation of a various agreements with BMS and Merck relating to the commercialization of Atripla, a triple combination product for the treatment of HIV.

Previous Experience

  • Northwestern University School of Law, Visiting Assistant Professor of Law (1998)
  • University of California, Davis, Visiting Professor (1999)
  • Daily Journal, "Top Health Care Lawyers" (2020)
  • Legal 500 US, Intellectual Property - Patents - Licensing (2017) and Media, Technology and Telecoms - Technology - Transactions (2015, 2017) 
  • Chambers USA, Life Sciences: Corporate/Commercial (2011-2014; 2019-2020)
  • The Daily Journal, Top Women Lawyers (2013)
  • LMG Life Sciences, "Life Science Star" (2013)
  • IAM Patent 1000 - The World’s Leading Patent Practitioners (2015-2016)
  • Northern California Rising Stars, Intellectual Property (2009-2010)